Current and historical daily PE Ratio for SRPT (
Sarepta Therapeutics Inc
) from 1997 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sarepta Therapeutics stock (SRPT) PE ratio as of Apr 19 2024 is 0.
More Details
Sarepta Therapeutics Inc (SRPT) PE Ratio (TTM) Chart
Sarepta Therapeutics Inc (SRPT) PE Ratio (TTM) Historical Data
View and export this data going back to 1997. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Sarepta Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
| 2024-04-08 | At Loss | 2024-02-05 | At Loss |
| 2024-04-05 | At Loss | 2024-02-02 | At Loss |
| 2024-04-04 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
| 2024-04-01 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
| 2024-02-27 | At Loss | 2023-12-26 | At Loss |
| 2024-02-26 | At Loss | 2023-12-22 | At Loss |
| 2024-02-23 | At Loss | 2023-12-21 | At Loss |
| 2024-02-22 | At Loss | 2023-12-20 | At Loss |
| 2024-02-21 | At Loss | 2023-12-19 | At Loss |
| 2024-02-20 | At Loss | 2023-12-18 | At Loss |
| 2024-02-19 | At Loss | 2023-12-15 | At Loss |
Sarepta Therapeutics Inc (SRPT) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8036071004
Share Class Description:
SRPT: Ordinary SharesCompare
Compare
Traded in other countries / regions
SRPT.USAAB3A.GermanyS1RP34.Brazil0L35.UK IPO Date
1997-06-04Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers